Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 81 to 90 of 281 total matches.
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
area of skin
and for the shortest duration possible.
DRUG INTERACTIONS — Roflumilast is a substrate ...
The FDA has approved a 0.3% foam formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of seborrheic
dermatitis in patients ≥9 years old. Roflumilast is
the first PDE4 inhibitor to be approved in the US for
this indication. It is also available in a 0.3% cream
formulation (Zoryve) for treatment of plaque psoriasis
and in an oral formulation (Daliresp, and generics) for
treatment of chronic obstructive pulmonary disease.
A 0.15% cream formulation for treatment of atopic
dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9 doi:10.58347/tml.2024.1700a | Show Introduction Hide Introduction
Letermovir (Prevymis) for CMV Prophylaxis
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
has not been
associated with myelotoxicity or nephrotoxicity.
▶ Many potentially troublesome drug interactions.
CMV ...
The FDA has approved letermovir (Prevymis – Merck),
a cytomegalovirus (CMV) DNA terminase complex
inhibitor, for prophylaxis of CMV infection and disease
in CMV-seropositive adult recipients of an allogeneic
hematopoietic cell transplant (HCT). Letermovir is
the first CMV DNA terminase complex inhibitor to
be approved in the US and the only drug specifically
indicated for CMV prophylaxis in HCT patients. It is not
approved for treatment of CMV infection.
Topical Roflumilast (Zoryve) for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
to severe
hepatic impairment (Child-Pugh B or C).
Drug Interactions: May interact with CYP3A4 inhibitors ...
The FDA has approved a 0.3% cream formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of plaque
psoriasis in patients ≥12 years old. Roflumilast is
the first topical PDE4 inhibitor to be approved by the
FDA for this indication; crisaborole (Eucrisa), another
topical PDE4 inhibitor, is approved for treatment
of atopic dermatitis. Oral roflumilast (Daliresp)
is approved for treatment of chronic obstructive
pulmonary disease.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):10-2 doi:10.58347/tml.2023.1668b | Show Introduction Hide Introduction
Comparison Table: H2-Receptor Antagonists and PPIs (online only)
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
Drug Some Available Oral Formulations Cost2
Usual Adult
Dosage1 Adverse Effects Drug Interactions ...
View the Comparison Table: H2-Receptor Antagonists and PPIs
Nifurtimox (Lampit) for Chagas Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
Effects: GI adverse effects such as nausea, anorexia,
and weight loss are common.
▶ Drug Interactions ...
The FDA has approved the nitrofuran antiprotozoal drug
nifurtimox (Lampit – Bayer) for treatment of Chagas
disease (American trypanosomiasis) in children who
weigh ≥2.5 kg. Nifurtimox was previously available in
the US only through a CDC-sponsored Investigational
New Drug (IND) program.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e123-4 doi:10.58347/tml.2024.1707h | Show Introduction Hide Introduction
Lumateperone (Caplyta) for Bipolar Depression
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
of an increased risk of death
in elderly patients with dementia-related psychosis.
DRUG INTERACTIONS ...
The oral second-generation antipsychotic drug
lumateperone (Caplyta – Intra-Cellular Therapies),
which was approved by the FDA in 2020 for treatment
of schizophrenia, is now approved for use as
monotherapy or as an adjunct to lithium or valproate
for treatment of depressive episodes associated with
bipolar I or II disorder in adults.
Remdesivir (Veklury) for COVID-19
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
. DRUG INTERACTIONS — Coadministration of remdesivir with chloroquine or hydroxychloroquine ...
The FDA has approved the antiviral drug remdesivir
(Veklury – Gilead) for IV treatment of COVID-19 in
hospitalized patients who are ≥12 years old and weigh
≥40 kg. Hospitalized children who are <12 years old
or weigh <40 kg can receive remdesivir through an
Emergency Use Authorization (EUA). Remdesivir is
the first drug to be approved in the US for treatment
of COVID-19.
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder
The Medical Letter on Drugs and Therapeutics • Jul 17, 2024 (Issue 5077)
, pyrexia, salivary
hypersecretion, and seasonal allergy are most common.
▶ Drug Interactions: Moderate ...
The FDA has approved ganaxolone (Ztalmy – Marinus)
for oral treatment of seizures associated with cyclin-dependent
kinase-like 5 (CDKL5) deficiency disorder
in patients ≥2 years old. It is the first drug to be
approved in the US for this indication.
Med Lett Drugs Ther. 2024 Jul 17;66(5077):1-2 doi:10.58347/tml.2024.5077a | Show Introduction Hide Introduction
Atogepant (Qulipta) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
adjustments may be needed for renal or hepatic impairment or for drug interactions.
2. Approximate WAC for 30 ...
Atogepant (Qulipta – Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ("gepant"), has been approved by the
FDA for prevention of episodic migraine in adults. It
is the second oral CGRP receptor antagonist to be
approved in the US for this indication; the first was
rimegepant (Nurtec ODT), which is also approved
for acute treatment of migraine. Parenteral CGRP
monoclonal antibodies are approved for prevention
of migraine (see Table 3).
In Brief: New Benzodiazepine Warnings
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020 (Issue 1610)
of benzodiazepines describing the potential for
these drugs to be abused and misused and to cause
addiction ...
The FDA now requires boxed warnings in the package
inserts of benzodiazepines describing the potential for
these drugs to be abused and misused and to cause
addiction and physical dependence. Benzodiazepine
labels have contained a boxed warning about a risk of
serious drug interactions with opioids since 2016.